Cannabis for psoriasis & eczema: CBD topical & ECS

Most importantly, the skin is one of the tissues most densely endowed with ECS components. CB2 on keratinocytes and mast cells regulates inflammation, proliferation and sebum – all of which are dysregulated in psoriasis.

At a glance:

CB2 on keratinocytes and mast cells regulates inflammation, proliferation and sebum directly in the skin
CBD significantly inhibited keratinocyte proliferation in vitro – direct effect on psoriasis pathomechanism
Topical CBD: penetrates the epidermis and acts locally via CB2, TRPV1 and PPAR-γ without a systemic effect

The endocannabinoid system in the skin

Overview hide

The endocannabinoid system in the skin

CBD for psoriasis: mechanism and studies

CBD for neurodermatitis (atopic dermatitis)

Topical CBD vs. systemic CBD for skin diseases

FAQ: Cannabis for skin diseases

Summary

The skin is the largest organ of the body and one of the tissues most densely endowed with ECS components. CB1, CB2, TRPV1, TRPV4 and PPAR-γ are detected in keratinocytes, melanocytes, hair follicles, sebaceous glands, mast cells and nerve fibers of the skin. The cutaneous ECS regulates:

– Proliferation and differentiation of keratinocytes (skin renewal)
– Sebum production (sebaceous glands via CB2)
– Inflammatory reactions (mast cells, T cells)
– Itch signal chain (TRPV1 in sensory nerve fibers)
– Barrier function of the epidermis

Dysregulation of the cutaneous ECS is associated with psoriasis, atopic dermatitis (neurodermatitis), acne and chronic pruritus.

CBD for psoriasis: mechanism and studies

Psoriasis is an autoimmune-mediated inflammatory skin disease with keratinocyte hyperproliferation. CBD acts on several levels:

Antiproliferative: Wilkinson & Williamson 2007 (J Dermatol Sci): CBD inhibits keratinocyte proliferation in a concentration-dependent manner via TRPV1 activation and CB1 inhibition of the EGF receptor.

Anti-inflammatory: CBD reduces TNF-α, IL-6, IL-1β – all key cytokines in psoriasis – in keratinocytes and mast cells. CB2 activation inhibits T-cell activation in the psoriasis circuit.

Study	Design	Result
Wilkinson & Williamson 2007 (J Dermatol Sci)	In vitro, keratinocytes, CBD	CBD inhibits keratinocyte proliferation at 0.1-10 µM; no toxicity; TRPV1-dependent
Palmieri et al. 2019 (Clin Ther)	Observational study, n=20, CBD cream for psoriasis and atopic dermatitis, 3 months	Significant improvement in skin hydration, elasticity, itching and sleep quality; no patient without improvement
Biro et al. 2009 (Trends Pharmacol Sci)	Review, cutaneous ECS	CB2 agonists in T cells inhibit psoriasis inflammatory cascade; topical ECS targeting proven as a therapeutic principle

CBD for neurodermatitis (atopic dermatitis)

Atopic dermatitis is characterized by a defective skin barrier, chronic inflammation and intense itching. CBD addresses all three:

Barrier function: PPAR-γ activation by CBD stimulates ceramide synthesis → improved epidermal barrier. Ceramide deficiency is a core defect in atopic dermatitis.

Itching (pruritus): TRPV1 in cutaneous nerve fibers mediates itch signals. CBD desensitizes TRPV1 → itch reduction without antihistamine side effects.

Inflammation: IL-4, IL-13 (Th2 cytokines in atopic dermatitis) are reduced by CB2 activation – similar mechanism as with dupilumab (biologic antibody).

Topical CBD vs. systemic CBD for skin diseases

For skin diseases, topical CBD (cream, serum, ointment) makes more sense than systemic administration:
– High local concentration directly on the target tissue
– No systemic effect (no degradation via liver, no CYP interactions)
– Systemic bioavailability very low (<1 %), locally sufficient for keratinocyte effect

Quality criteria for CBD skin products:
– COA-tested CBD content (often declared too low or too high)
– Liposomal or nanoemulsified formulation increases skin penetration
– No alcohol carrier for neurodermatitis (drying)
– Ceramides and panthenol as additional barrier supporters

Study highlight: Wilkinson & Williamson 2007 (J Dermatol Sci): CBD significantly inhibited keratinocyte proliferation in vitro – direct mechanism of action in psoriasis plaques. Topical CBD penetrates the epidermis and acts locally via CB2, TRPV1 and PPAR-γ without systemic effects.

More on the topic:

Cannabis & the immune system
Comparison of forms of consumption

FAQ: Cannabis for skin diseases

Summary

Cutaneous ECS is one of the best understood and most accessible ECS areas. CBD has an antiproliferative effect on keratinocytes (psoriasis), an anti-inflammatory effect via CB2/TRPV1 and reduces itching via TRPV1 desensitization (neurodermatitis). Topical CBD is more useful for skin diseases than systemic use – high local concentration, no interactions. CBD dosage guide for systemic use for comorbidities; check interactions with dermatologicals (cyclosporine, methotrexate) with a doctor.

Cannabis prescription online? Our teleclinic comparison shows all 31 providers in direct comparison – with prices, waiting times and real reviews. Free and independent.